View publication ↗Market Analysis · 01September 2026
Beyond Spectacle Independence
How the premium IOL market is shifting from maximum range to better quality of vision
Version 1.1 · 12 pagesView publication →
Ophthalmic Intelligence Europe
Evidence,
interpreted.
Independent ophthalmic intelligence across Market Analysis, Evidence Reviews and Frameworks.
Explore publications ↗Independent · Evidence-led · Clinically focused
Selected publications
View all 8 publications →View publication ↗
View publication ↗Evidence Review · 05September 2026
FineVision HP
Established optical lineage. Contemporary hydrophobic platform.
Version 1.0 · 12 pagesView publication →
Frameworks
Explore frameworks →
View publication ↗Framework · 2026October 2026
Functional Vision & Patient Outcomes Framework
Integrating consensus-based functional IOL classification with patient-centred outcomes and evidence certainty.
Version 1.1 · 3 pagesView publication →
View publication ↗Framework · 202613 October 2026
Clinical IOL Decision Pathway
An evidence-informed clinical pathway integrating patient priorities, ocular suitability, corneal optics, surgical astigmatism and individualized IOL selection.
Version 1.4 · 4 pagesView publication →
View publication ↗Framework · 202614 October 2026
Refractive Enhancement After Presbyopia-Correcting IOLs
Enhancement evidence and secondary refractive strategies, with a clinical decision tree and six patient scenarios.
Version 1.3 · 11 pagesView publication →
Why OIE
The right distinctions.
A clearer clinical picture.
01
Measured
What does the optical or technical evidence demonstrate?
02
Demonstrated
What has translated into clinical outcomes?
03
Uncertain
What remains plausible, emerging or unproven?
Clarity without
overstatement.
How we evaluate evidence →01
Established
02
Supported
03
Emerging
04
Not yet established
Editorial evidence descriptors — not formal GRADE ratings.
Beyond Publications
Advisory & Custom Research
Independent scientific assessment and clinical intelligence tailored to specific research, technology and strategic questions.